SEC Form 4 · accession 0001193125-26-285722
SAB Biotherapeutics, Inc. · SABS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexandra Kropotova
Officer — CHIEF MEDICAL OFFICER
Period of report
Jun 25, 2026
Accepted (ET)
Jun 26, 2026 · 5:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001833214
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 25, 2026 | F | 988 | — | D | 42,308 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of the Issuer's common stock ("Common Stock") withheld to statisfy tax withholding requirements on the vesting of the Issuer's restricked stock units ("RSUs").
- F2Includes 37,158 shares of Common Stock and 5,150 shares of Common Stock which remain subject to vesting of RSUs granted under the Issuer's 2021 Equity Incentive Plan, as amended.
- F3Each RSU represents a contingent right to receive one share of Common Stock.